论文部分内容阅读
Objective:Taliglucerase alfa is a β-glucosidase enzyme replacement therapy approved in the USA and other countries for treatment of Gaucher disease (GD) in adults,and the first approved plant cell-expressed recombinant protein.In this study,we aimed to assess the efficacy and safety of taliglucerase alfa in pediatric patients with GD.